Comparison between sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors on the risk of incident cancer in patients with diabetes mellitus: A real-world evidence study.
Hui-Lin SungChuan-Yu HungYu-Chun TungChih-Chung LinTung-Han TsaiKuang-Hua HuangPublished in: Diabetes/metabolism research and reviews (2024)
SGLT-2i use was associated with a significantly lower risk of cancer than DPP-4i use.